Biotechnology Weekly Briefs
Every published Biotechnology brief — the week’s developments and what they mean for operators, vendors, and investors.
- Licensing Outpaces Equity, Capital Chases Inspection-Ready Manufacturing, and Biotech Monetizes PipelinesAugust 31, 2026
- Biosimilar rights become launch engines, AI enters regulated trial operations, and margins come under pressureAugust 24, 2026
- IP Clarity, Mega-Rounds, and Approval-Contingent Capital Redefine Biotech DealmakingAugust 17, 2026
- Execution Becomes the Moat, AI Moves into Workflow Control, and Commercial Infrastructure Commands the PremiumAugust 10, 2026
- Reserved capacity, state-backed biologics execution, and platform-premium M&A reshape dealmakingAugust 3, 2026
- Platform reproducibility, regulated in vivo editing, and late-stage assets are capturing the capital poolJuly 27, 2026